Financing drug discovery for orphan diseases
Recently proposed ‘megafund’ financing methods for funding translational medicine and drug development require billions of dollars in capital per megafund to de-risk the drug discovery process enough to issue long-term bonds. Here, we demonstrate that the same financing methods can be applied to orp...
Main Authors: | Gromatzky, Austin A., Stein, Roger Mark, Fernandez, Jose-Maria, Fagnan, David E., Lo, Andrew W |
---|---|
Other Authors: | Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory |
Format: | Article |
Language: | en_US |
Published: |
Elsevier B.V.
2014
|
Online Access: | http://hdl.handle.net/1721.1/90835 https://orcid.org/0000-0003-2944-7773 |
Similar Items
-
Risk and Reward in the Orphan Drug Industry
by: Lo, Andrew W, et al.
Published: (2021) -
Risk and Reward in the Orphan Drug Industry
by: Lo, Andrew W, et al.
Published: (2022) -
Analytics for financing drug development
by: Fagnan, David Erik
Published: (2015) -
Can Financial Engineering Cure Cancer?
by: Fernandez, Jose-Maria, et al.
Published: (2014) -
Financing drug discovery via dynamic leverage
by: Frishkopf, John J., et al.
Published: (2017)